Efficacy and safety of decamethoxin in complex treatment of patients with group III viral-bacterial community-acquired pneumonia


BACKGROUND. There are many unsolved medical problems and, of course, pneumonia is one of them. Communityacquired pneumonia (CAP) is a multifactorial disease, but the role of viruses as causative agents is constantly growing. Specific antiviral therapy for CAP is limited. Therefore, the search for drugs with virucidal activity remains relevant. An antimicrobial agent with a broad spectrum of action – decamethoxin – is successfully used today for treatment of patients with infectious exacerbations of bronchial asthma and chronic bronchitis. At the same time efficacy of decamethoxin in CAP patients was not studied.

OBJECTIVE. To evaluate the effectiveness and safety of the inhaled antimicrobial drug decamethoxin in the complex treatment of patients with group III viral-bacterial CAP.

MATERIALS AND METHODS. There was enrolled 62 patients with group III viral-bacterial CAP. All patients received the same sequential antibiotic therapy: protected aminopenicillin with macrolide or III generation cephalosporin with macrolide. Patients of the main group were prescribed inhalations through a nebulizer of the antiseptic drug decamethoxin in addition to antibacterial therapy from the first day of treatment for 5-7 days.

RESULTS AND DISCUSSION. No adverse events were detected in any of the patients during treatment. In all cases, recovery was diagnosed. At the same time, the term of achieving positive results in the main group was 12.2±0.7 days, and in the control – 17.2±0.7 (р <0,05). The average duration of antibiotic use was different in main and control groups: respectively 9.4±0.4 and 10.7±0.4 days (р <0,05). There were no infectious complications in the patients of the main group, while 24 (72 %) patients of the control group were diagnosed with acute rhinopharyngitis (47.0 % of cases), lateral pharyngitis (13 %) and sinusitis (9 %), other complications (otitis, infectious exudative pericarditis). In 22 (66 %) cases there was one complication and in 2 (6 %) cases there were two complications.

CONCLUSIONS. For patients with group III viral-bacterial CAP additional inclusion in the empirical sequential antibiotic therapy of inhaled decamethoxin can significantly reduce the frequency of infectious complications, duration of antibiotic therapy, as well as the duration of positive treatment results.

Keywords: community-acquired pneumonia, viral-bacterial pneumonia, empirical antibiotic therapy, stepwise antibiotic therapy, antimicrobial drugs, decamethoxin.


Adapted evidence-based clinical guideline “Nosocomial pneumonia in adults: etiology, pathogenesis, classification, diagnosis, antimicrobial therapy and prevention”. – Kyiv: National Academy of Medical Sciences of Ukraine, 2019. – 94 p.

GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study (2017). Lancet Inf. Dis. 2018; 10; 392 (10159): 1736-1788. DOI: 10.1016/S0140-6736(18)32203-7.

Noviello S., Huang D. The basics and the advancements in diagnosis of bacterial lower respiratory tract infections. Diagnostics. 2019; 9 (37). DOI: 10.3390/diagnostics9020037.

Battle against Respiratory Viruses (BRaVe) initiative. World Health Organisation. Available at: https://www.who.int/influenza/patient_care/clinical/brave/en (last accessed: 15.03.2021).

Jain S. et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N. Engl. J. Med. 2015; 373: 415-427. DOI: 10.1056/NEJMoa1500245.

Chapter 18. Acute lower respiratory infections. ERS White Book. Available at: https://www.erswhitebook.org/files/public/Chapters/18_ALRIs.pdf (last accessed: 15.03.2021).

Woodhead M. et al. Guidelines for the management of adult lower respiratory tract infections. Clinical Microbiology and Infection. 2011; 17 (6): E1-E59. DOI: 10.1111/j.14690691.2011.03672.x.

Pneumonia in adults: diagnosis and management. NICE Clinical Guidelines, No. 191. London: National Institute for Health and Care Excellence (UK), 2019. Available at: https://www.ncbi.nlm.nih.gov/books/NBK552669 (last accessed: 15.03.2021).

Dziublyk Y.O. The choice of antibiotic therapy in patients with nosocomial lower respiratory tract infections of bacterial etiology is reasonable. Ukr. Pulmonol. J. 2012; 3: 60-64.

Lagi F., Pollini S., Zammarchi L. Clinical role of viral identification by a polymerase chain reaction-based diagnostic panel in adults hospitalized with community-acquired pneumonia. Intern. Emerg. Med. 2020; 15: 563-565. DOI: https://doi.org/10.1007/s11739-020-02282-7.

Evidence-based clinical guidelines “Influenza and acute respiratory infections”. – Kyiv: National Academy of Medical Sciences of Ukraine, 2018. – 141 p.

Dandachi D., Rodriguez-Barradas M. Viral pneumonia: etiologies and treatment. Journal of Investigative Medicine. 2018; 66: 957-965.

Bellinghausen C. et al. Viral-bacterial interactions in the respiratory tract. Journal of General Virology. 2016; 97 (12). DOI: https://doi.org/10.1099/jgv.0.000627.

Ruuskanen O. et al. Viral pneumonia. The Lancet. 2011; 377 (9773): 1264-1275. DOI: https://doi.org/10.1016/S0140-6736(10)61459-6.

Tatarelli P. et al. Prevalence and clinical impact of VIral Respiratory tract infections in patients hospitalized for Community-Acquired Pneumonia: the VIRCAP study. Internal and Emergency Medicine. 2019. DOI: https://doi.org/10.1007/s11739-019-02243-9.

Ferreira-Coimbra J., Sarda C., Rello J. Burden of community-acquired pneumonia and unmet clinical needs. Adv. Ther. 2020; 37: 1302-1318. DOI: https://doi.org/10.1007/s12325-020-01248-7.

Bjarnason A., Westin J., Lindh M. et al. Incidence, etiology, and outcomes of community-acquired pneumonia: a population-based study. Open Forum Infect. Dis. 2018; 5 (2): ofy010. DOI: 10.1093/ofid/ofy010.

Dandachi D., Rodriguez-Barradas M. Viral pneumonia: etiologies and treatment. J. Investig. Med. 2018; 66 (6): 957-965. DOI: http://dx.doi.org/10.1136/jim-2018-000712.

Gumeniuk M.I., Gumeniuk G.L., Opimakh S.G. Efficacy of decamethoxine against complex viruses, regardless of their antigenic structure: prospects for use in modern viral diseases of the respiratory tract. Topical Infectology. 2020. Available at: http://ai.zaslavsky.com.ua/article/view/196168/197747 (last accessed: 04.06.2020).

Zab Mosenifar. What is the prevalence of viral pneumonia? Medscape. 2020. Available at: https://www.medscape.com/answers/300455-107810/whatis-the-prevalence-of-viral-pneumonia (last accessed: 15.03.2021).

Metlay J.P. et al. Diagnosis and treatment of adults with communityacquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. American Journal of Respiratory and Critical Care Medicine. 2019; 200 (7). DOI: https://doi.org/10.1164/rccm.201908-1581ST.

Paliy V.G. et al. Rationale for the medical use of antimicrobials containing decamethoxine. Bukovynian Medical Bulletin. 2017; 1 (81): 100-105.

Instructions for medical use of the drug Decasan® (Decasanum): approved by order of the Ministry of Health dated 22.12.2016 № 1391. Available at: http://mozdocs.kiev.ua/likiview.php?id=41615 (last accessed: 15.03.2021).

Shuvam Chaudhuri et al. Innovation and trends in the development and approval of antiviral medicines: 1987-2017 and beyond. Antiviral Research. 2018; 155: 76-88. DOI: 10.1016/j.antiviral.2018.05.005.

World Pneumonia Day is Nov. 12, 2017; Stop Pneumonia: strengthen strategies to protect, prevent and treat. Available at: https://www.thoracic.org/about/newsroom/press-releases/journal/2017/world-pneumonia-dayis-nov-12-stop-pneumonia-strengthen-strategies-to-protect-prevent-andtreat.php (last accessed: 15.03.2021).

Trokhymenko O.P. et al. Determination of in vitro virucidal action of decamethoxine in models of simple and complex viruses as possible triggers of infectious exacerbation of bronchial asthma. Preventive Medicine. 2013; 3-4 (21): 78-84.

FDA Approves First Treatment for COVID-19. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatmentcovid-19 (last accessed: 16.03.2021).

Dziublyk O.Y., Dziublyk I.V., Trokhymenko O.P. et al. Virulicidal action of decamethoxine in vitro against coronavirus of infectious bronchitis. Ukr. Pulmonol. J. 2020; 2: 27-30. DOI: 10.31215/2306-4927-2020-108-2-27-30.

Panchuk S.I. et al. Virulicidal action of decamethoxine in relation to viral triggers of infectious exacerbation of bronchial asthma. Ukr. Pulmonol. J. 2014; 2: 48-51.

Khaleeva O.L., Pecheneg L.O. Prospects for the use of quaternary ammonium base salts in mild drugs for the treatment of dermatomycoses. Ukr. Biopharmaceutical J. 2012; 3 (20): 28-32.

Gumeniuk M.I., Opimakh S.G., Gumeniuk G.L. et al. Decamethoxine: care for patients with infectious exacerbations of bronchial asthma. Ukr. Pulmonol. J. 2019; 2: 25-32. DOI: 10.31215/2306-4927-2019-104-2-25-32.

Dziublyk O.Y., Gumeniuk M.I., Capitan G.B. et al. Efficacy and safety of inhaled decamethoxine in the treatment of patients with infectious exacerbation of chronic bronchitis. Asthma and Allergy. 2015; 4: 22-27.

Kovalchuk V.P. et al. Microbiological substantiation of expediency of combined use of antibiotics and Dekasan. Emergency Medicine. 2017; 8 (87): 39-42. DOI: 10.22141/2224-0586.8.87.2017.121324.

Influenza (Flu) Antiviral Drugs and Related Information. Available at: https://www.fda.gov/drugs/information-drug-class/influenza-flu-antiviral-drugs-and-related-information#ApprovedDrugs (last accessed: 15.03.2021).

WHO Solidarity Trial Consortium, Pan H. et al. Repurposed antiviral drugs for COVID-19 – interim WHO Solidarity Trial results. MedRxiv. 2020. DOI: https://doi.org/10.1101/2020.10.15.20209817.

Charlton C.L. et al. Practical guidance for clinical microbiology laboratories: viruses causing acute respiratory tract infections. Clin. Microbiol. Rev. 2019; 32 (1): e00042-18. DOI: 10.1128/CMR.00042-18.

FDA Approves New Drug to Treat Influenza. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatinfluenza (last accessed: 16.03.2021).

Ison M., Hayden F. Antiviral agents against respiratory viruses. Infectious Diseases (Fourth Edition). 2017; 2: 1318-1326.e2. DOI: https://doi.org/10.1016/B978-0-7020-6285-8.00154-4.

How to Cite
Bororova, O. (2021). Efficacy and safety of decamethoxin in complex treatment of patients with group III viral-bacterial community-acquired pneumonia. Infusion & Chemotherapy, (1), 15-21. https://doi.org/10.32902/2663-0338-2021-1-15-21

Author Biography

O.L. Bororova, SI “National Institute of Phthisiology and Pulmonology named after F.G. Yanovsky of the NAMS of Ukraine”, Kyiv, Ukraine

Olena Leonidivna Bororova
Junior Researcher of the Department of Treatment Technologies for Nonspecific Lung Diseases
10, M. Amosova st., Kyiv, 03038, Ukraine.
E-mail: elena_bororova@ukr.net

Most read articles by the same author(s)